Julio Rosenstock

Endocrinology — Medical City Dallas Hospital, United States

LeadR Profile

Julio Rosenstock Medical City Dallas Hospital United States
3 978 ScienceLeadR Reputation 3978
Network Map

Endocrinology

Subspecialties: Cardiology - Nephrology - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026

Source: PubMed

The University of Texas Southwestern Medical Center

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 579

Citations

Citations: 92 767 1st author: 151 Last author: 78 Unique author: 11


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.
muscles, anti-obesity agents, body composition, obesity, muscle, skeletal, tissues, adipose tissue, weight control, semaglutide
Diabetes Obes Metab20260
Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial.
aldehyde reductase, oxidoreductases, diabetic cardiomyopathies, cardiovascular diseases, disease progression, cardiomyopathies
Open Heart20260
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
diabetes mellitus, glucagon-like peptide 1, receptors, islet amyloid polypeptide, safety, amylin receptor agonists, drug-related side effects and adverse reactions, therapeutics, islet amyloid polypeptide, diabetes mellitus, type 2
Lancet Top journal20262
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
diabetes mellitus, glucagon-like peptide 1, receptors, islet amyloid polypeptide, safety, amylin receptor agonists, drug-related side effects and adverse reactions, therapeutics, islet amyloid polypeptide, diabetes mellitus, type 2
Lancet Top journal20262
Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.
glucagon-like peptide 1, safety, gastric emptying, liver, appetite, obesity, weight loss, overweight, pharmacokinetics
Obesity (Silver Spring)20260

Clinical Studies 154

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 106
Phase 2 37
Phase 4 8
N/A 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 145
Terminated 4
Active not recruiting 3
Not yet recruiting 1
Recruiting 1

By type:

Interventional 153
Observational 1

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 3
multicentric5to9 4
multicentricup10 137

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD 0801 in Subjects with Type 2 Diabetes Mellitus
NCT06731075 — diabetes mellitus, safety, insulin, multiple chronic conditions, capsules, glycemic control, diabetes mellitus, type 2
Phase 3Not yet recruiting2025
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym (Mifepristone) (CATALYST)
NCT05772169 — diabetes mellitus, tablets, prevalence, therapeutics, mifepristone, adrenocortical hyperfunction, cushing syndrome, diabetes mellitus, type 2
Phase 4Recruiting2023
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796 — safety, body weight, obesity, research, overweight, semaglutide
Phase 3Active not recruiting2022
Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH)
NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide
Phase 3Active not recruiting2021

LeadR Networks

Main global connection map